As of November 8, 2026, Ernexa Therapeutics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 26, 2026 to September 16, 2026 (Form 8-K, September 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ernexa Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ernexa Therapeutics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-26 to 2026-09-16. Every row below is cited to the filing it comes from, and this page adds each new change as Ernexa Therapeutics Inc. files it.
Also on the record for Ernexa Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Freebird Partners LP | 7% of the class | 5%+ stakes | Source |
| May 20, 2026 | Stake report, Schedule 13G/A, by Clear Street LLC | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Freebird Partners LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by John D. Halpern | 5.6% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by Bleichroeder LP | 6.86% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by Clear Street LLC | 12.8% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Shameek Konar | 9.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13D/A, by Charles Cherington | 34.7% of the class | 5%+ stakes | Source |
| December 19, 2025 | Stake report, Schedule 13G/A, by Freebird Partners LP | 9.9% of the class | 5%+ stakes | Source |
| December 16, 2025 | Stake report, Schedule 13G/A, by Shameek Konar | 7.12% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13G/A, by IAF, LLC | 4.1% of the class | 5%+ stakes | Source |
| April 11, 2025 | Form D, private offering | $7.25M sold | Form D page | Source |
Selling to them or working with them? See who runs Ernexa Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Ernexa Therapeutics Inc. and the records around it.
Ernexa Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Apr 2025
- Who owns it
Companies that share a holder
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
- Clear Street LLC also filed stake reports on 16 other companies: Integrated Wellness Acquisition Corp (Aug 2026), StoneBridge Acquisition II Corporation (Aug 2026), ConnectM Technology Solutions, Inc. (May 2026)
Watch Ernexa Therapeutics Inc.
Get an email when Ernexa Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ernexa Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ernexa Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ernexa Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | Reported | not named in the filing | 8-K, 2026-09-16 | ||
| 2026-06-26 | Reported | not named in the filing | 8-K, 2026-06-26 |
New leaders reset buying decisions — get the Full Report on Ernexa Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Ernexa Therapeutics Inc., with the record behind each one.
Find candidates like senior executive at Ernexa Therapeutics Inc.Every change, in the filing's words
Reported
On September 14, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the "Board") of Ernexa Therapeutics Inc., a Delaware corporation (the " Company ", " we ", " us ", or " our ") approved the appointment of Robert J. Spiegel, M.D. to serve as a member of the Board, effective immediately.
- Dr. Spiegel will serve until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
- Dr. Spiegel will be compensated in accordance with the Company's Board of Directors Compensation Plan adopted effective August 15, 2026, as described in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.
Reported
On June 22, 2026, Sandra Gurrola, Senior Vice President of Finance of Ernexa Therapeutics Inc., a Delaware corporation (the " Company "), delivered her notice of resignation, with such resignation becoming effective July 3, 2026.
- Ms. Gurrola's resignation was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Following the effective date of her resignation, Ms. Gurrola has agreed to provide transition assistance to the Company on a part-time basis for up to 10 hours per week through the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
- The Company has not yet determined the compensation, if any, payable to Ms. Gurrola for such transition services.
- If the Company enters into or approves a material compensatory arrangement with Ms. Gurrola in connection with her resignation or transition services, the Company will disclose such arrangement in accordance with applicable SEC rules.
- The Company has initiated a search to identify a successor.
- Until a successor is appointed, the Company expects to use additional outside support to assist with finance, accounting, and reporting matters.
Tools for this story
Each opens in a new tab, filled in for Ernexa Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.